Exact Mass: 249.0914
Exact Mass Matches: 249.0914
Found 184 metabolites which its exact mass value is equals to given mass value 249.0914,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
S-Acetyldihydrolipoamide
S-Acetyldihydrolipoamide is a thio-acetylated form of dihydrolipoamide. The molecule is commonly conjugated to lysine residues. The structure shown is the free form of the molecule. Pyruvate dehydrogenase complex. The reaction is 2-(alpha-hydroxyethyl)-TPP + lipoamide => S-acetyldihydrolipoamide + TPP [Homo sapiens], occuring in mitochondrial matrix. (reactome.org). S-Acetyldihydrolipoamide is an intermediate in alanine, aspartate and pyruvate metabolism and glycolysis/gluconeogenesis (KEGG:C01136). It is converted from 2-hydroxyethyl-THPP and lipoamide via the enzyme pyruvate dehydrogenase (EC:1.2.4.1). It is then converted to acetyl-CoA via the enzyme pyruvate dehydrogenase E2 component (dihydrolipoamide acetyltransferase) (EC:2.3.1.12). S-Acetyldihydrolipoamide is a thio-acetylated form of dihydrolipoamide. The molecule is commonly conjugated to lysine residues. The structure shown is the free form of the molecule.
S-Acetyldihydrolipoamide-E
The acetyl thioester of the reduced lipoyllysine residue in dihydrolipoyllysine-residue acetyltransferase (EC2.3.1.12). S-Acetyldihydrolipoamide-E is a reactant or product of enzyme EC 1.2.4.1. S-Acetyldihydrolipoamide-E is a reactant or product of enzyme EC 2.3.1.12. (PubChem sid=47205563) [HMDB] The acetyl thioester of the reduced lipoyllysine residue in dihydrolipoyllysine-residue acetyltransferase (EC2.3.1.12). S-Acetyldihydrolipoamide-E is a reactant or product of enzyme EC 1.2.4.1. S-Acetyldihydrolipoamide-E is a reactant or product of enzyme EC 2.3.1.12. (PubChem sid=47205563).
(1Z)-1-(3-Ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one
2',3'-Didehydro-2',3'-dideoxyguanosine
Benzo(f)quinolin-3(2H)-one, 8-chloro-1,4,4a,5,6,10b-hexahydro-4-methyl-, trans-
Me glycoside,N-Ac-alpha-D-Pyranose-4-Amino-4-deoxyglucuronic acid
S-Acetyldihydrolipoamide-E
2,5-Dimethoxy-4-(trifluoromethyl)phenethylamine
(S)-2-(Benzyloxycarbonylamino)-3-butenoic acid methyl ester
(R)-4-benzyl-5-oxomorpholine-3-carboxylic acid methyl ester
4-[4-(TERT-BUTYL)PHENYL]-5-MERCAPTO-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE
1-CHLORO-3-(1,3,3-TRIMETHYL-1,3-DIHYDRO-INDOL-2-YLIDENE)-PROPAN-2-ONE
Benzoic acid,4-[(1,3-dioxobutyl)amino]-, ethyl ester
Ethyl 3,7-dimethyl-4H-benzo[1,4]thiazine-2-carboxylate
Bay H 2049
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor
Phenol,2-[[(phenylmethyl)amino]methyl]-, hydrochloride (1:1)
(2S,3R)-2-Methyl-5-oxo-4-(phenylmethyl)-3-Morpholinecarboxylic acid
(1-thieno[3,2-d]pyrimidin-4-ylpiperidin-4-yl)methanol
1-PHENYL-3-PYRIDIN-3-YL-1H-PYRAZOLE-4-CARBALDEHYDE
(4-methoxyphenyl)(phenyl)methanamine hydrochloride
1-(2-ethoxyphenyl)-5-oxopyrrolidine-3-carboxylic acid
ETHYL5-AMINO-1-(2-FLUOROPHENYL)-1H-PYRAZOLE-3-CARBOXYLATE
2-Oxazolidinone, 5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-, (5R)-
ethyl 5-amino-1-(4-fluorophenyl)pyrazole-4-carboxylate
(S)-2-(((Benzyloxy)carbonyl)amino)pent-4-enoic acid
[4-(4-methylphenoxy)phenyl]methanamine,hydrochloride
ETHYL5-AMINO-1-(3-FLUOROPHENYL)-1H-PYRAZOLE-4-CARBOXYLATE
ETHYL5-AMINO-1-(2-FLUOROPHENYL)-1H-PYRAZOLE-4-CARBOXYLATE
2-AMINO-BENZOTHIAZOLE-6-CARBOXYLIC ACID SEC-BUTYLAMIDE
4-ethyl-3-[(2-methylphenoxy)methyl]-1H-1,2,4-triazole-5-thione
4-ETHYL-5-[(4-METHYLPHENOXY)METHYL]-4H-1,2,4-TRIAZOLE-3-THIOL
1-(2-Methoxybenzyl)-5-oxopyrrolidine-3-carboxylic acid
4-ethyl-3-(1-phenoxyethyl)-1H-1,2,4-triazole-5-thione
(R)-2-(((Benzyloxy)carbonyl)amino)pent-4-enoic acid
(2S,4R)-METHYL 1-BENZOYL-4-HYDROXYPYRROLIDINE-2-CARBOXYLATE
4-(2-TRIFLUOROMETHYL-PHENOXY)-PIPERIDINEHYDROCHLORIDE
1-PHENYL-3-PYRIDIN-4-YL-1H-PYRAZOLE-4-CARBALDEHYDE
(S)-4,9-DIHYDRO-1-METHYL-3H-PYRIDO[3,4-B]INDOLE-3-CARBOXYLICACID
1-(3-HYDROXYPHENYL)-1-METHOXY-1-(2-THIAZOLYL)-PROPANE
1-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazine
6-(benzo[d][1,3]dioxol-5-ylmethyl)-2-thia-6-azaspiro[3.3]heptane
(R)-Benzyloxycarbonylamino-cyclopropyl-acetic acid
(2,3-Dihydro-benzo[1,4]dioxin-2-yl)-((S)-3-hydroxy-pyrrolidin-1-yl)-Methanone
(2,3-Dihydro-benzo[1,4]dioxin-2-yl)-((R)-3-hydroxy-pyrrolidin-1-yl)-Methanone
METHYL 7-ALLYL-6-HYDROXY-5-OXO-1,2,3,5-TETRAHYDROINDOLIZINE-8-CARBOXYATE
1-(4-METHOXY-BENZYL)-5-OXO-PYRROLIDINE-3-CARBOXYLIC ACID
3-(2-NITROPHENYL)-2-PROPENOIC ACID1,1-DIMETHYLETHYL ESTER
bexlosteride
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D065088 - Steroid Synthesis Inhibitors D004791 - Enzyme Inhibitors > D065088 - Steroid Synthesis Inhibitors > D058891 - 5-alpha Reductase Inhibitors C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C242 - Anti-Androgen C471 - Enzyme Inhibitor > C2319 - 5 Alpha-Reductase Inhibitor C1892 - Chemopreventive Agent
N,N-dimethyl-2-[(5-phenyl-1,3,4-oxadiazol-2-yl)thio]ethanamine
N-(4,5-dimethyl-1,3-benzothiazol-2-yl)propanehydrazide
5-(4-Chlorophenyl)-6-ethylpyrimidin-3-ium-2,4-diamine
(1E)-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one
2-amino-9-[5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-1H-purin-6-one
N-(2,3-dihydro-1H-inden-1-yl)-N-prop-2-ynylmethanesulfonamide
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D004791 - Enzyme Inhibitors > D008996 - Monoamine Oxidase Inhibitors D020011 - Protective Agents
8,5-Cyclo-2-deoxyadenosine
An organic heterotetracyclic compound obtained by intramolecular formation of a C-C bond between positions 8 and 5 of 2-deoxyadenosine.
2-(4,5-dihydro-1H-imidazol-2-ylthio)-N-(4-methylphenyl)acetamide
Propionylamino-acetic acid 2-oxo-2-phenyl-ethyl ester
(R)-S(6)-acetyldihydrolipoamide
The (R)-enantiomer of S(6)-acetyldihydrolipoamide.
5-acetamido-3,5-dideoxy-L-arabino-hept-2-ulopyranosonic acid
1H-Indole-2,3-dione, 5-methoxy-1-(trimethylsilyl)-
ML351
ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC50 of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2[1].?ML351 prevents dysglycemia and reduces β-cell oxidative stress in nonobese diabetic mouse model of T1D[2].
SY-LB-35
SY-LB-35 is a potent bone morphogenetic protein (BMP) receptor agonist. SY-LB-35 can stimulate significant increases in cell number and cell viability in the C2C12 myoblast cell line, and causes shifts towards the S and G2/M phases of the cell cycle. SY-LB-35 stimulates canonical Smad and non-canonical PI3K/Akt, ERK, p38 and JNK intracellular signaling pathways[1].
